This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

New Clinical Results Further Distance The BIRMINGHAM HIP™ Resurfacing System From Failed Metal-on-Metal Hip Implants

LONDON, February 9, 2012 /PRNewswire/ --  Smith & Nephew (NYSE:SNN; LSE:SN), the global medical technology business, today announced the results of a new study for its BIRMINGHAM HIP™  Resurfacing (BHR) System. The study, carried out at the request of the FDA, followed the progress of the first 400 BHR patients in the United Kingdom and found that after 10 years, 99% were either satisfied or extremely satisfied with their BHR procedure.

"These results further exemplify why the BHR Hip is unlike any other metal-on-metal implant," says John Soto, Senior Vice President for Smith & Nephew's Global Hip Franchise. "Not only does the BHR Hip offer all the advantages of hip resurfacing, including bone-conservation, greater range of motion and decreased risk of dislocation, but it does so while maintaining implant survivorship rates that are on par with, or in some patient populations even better than, traditional total hip replacement which has long been considered the most successful orthopaedic surgical procedure for relieving chronic pain."

In addition to patient satisfaction, the 10-year BHR data showed:
  • The Oswestry Modified Harris Hip Score (OMHHS) averaged 92.5 points – demonstrating excellent long-term clinical implant function.[i]
  • The implant survival rate according to the Kaplan-Meier analysis was 95.9%  - well exceeding the 10-year survivorship threshold of 90% for implants as established by the National Institute for Health and Clinical Science (NICE)[ii]
  • A radiographic success rate of 99.7% was observed by independent radiographic review.

Recently, several metal-on-metal hip implants have been taken off the market by other device companies due to higher than expected failure rates and increasing patient safety concerns. The latest results show that the BHR Hip stands apart from these and many other metal-on-metal resurfacing devices. Key features of the BHR Hip that contribute to this success include its distinctive metallurgy and its sophisticated design geometry.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,781.36 -17.13 -0.10%
S&P 500 2,088.77 -1.34 -0.06%
NASDAQ 5,126.19 -1.3350 -0.03%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs